{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:52:25Z","timestamp":1785595945465,"version":"3.56.0"},"reference-count":43,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,5,25]]},"DOI":"10.1253\/circj.cj-25-0942","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:08:34Z","timestamp":1774908514000},"page":"581-591","source":"Crossref","is-referenced-by-count":1,"title":["High Human Epididymis Protein 4 Levels Are Associated With Lower Systolic Function and Poor Prognosis in Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1253","volume":"90","author":[{"given":"Yuki","family":"Okuno","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Hanatani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kuyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Usuku","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seitaro","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Izumiya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Soejima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology, Faculty of Life Sciences, Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University"},{"name":"Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation<\/i> 2022; 145: e876\u2013e894, doi:10.1161\/CIR.0000000000001062.","DOI":"10.1161\/CIR.0000000000001062"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K, et al. HF STATS 2024: Heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America. <i>J Card Fail<\/i> 2025; 31: 66\u2013116, doi:10.1016\/j.cardfail.2024.07.001.","DOI":"10.1016\/j.cardfail.2024.07.001"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Savarese G, Uijl A, Ouwerkerk W, Tromp J, Anker SD, Dickstein K, et al. Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Fail<\/i> 2022; 9: 2107\u20132118, doi:10.1002\/ehf2.13917.","DOI":"10.1002\/ehf2.13917"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Tsutsui H, Albert NM, Coats AJS, Anker SD, Bayes-Genis A, Butler J, et al. Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. <i>Eur J Heart Fail<\/i> 2023; 25: 616\u2013631, doi:10.1002\/ejhf.2848.","DOI":"10.1002\/ejhf.2848"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Ho FK, Mark PB, Lees JS, Pell JP, Strawbridge RJ, Kimenai DM, et al. A proteomics-based approach for prediction of different cardiovascular diseases and dementia. <i>Circulation<\/i> 2025; 151: 277\u2013287, doi:10.1161\/CIRCULATIONAHA.124.070454.","DOI":"10.1161\/CIRCULATIONAHA.124.070454"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Fujimoto W, Odajima S, Okamoto H, Iwasaki M, Nagao M, Konishi A, et al. Importance of B-type natriuretic peptide in the detection of patients with structural heart disease in a primary care setting. <i>Circ J<\/i> 2024; 88: 732\u2013739, doi:10.1253\/circj.CJ-23-0930.","DOI":"10.1253\/circj.CJ-23-0930"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. LeBleu VS, Teng Y, O\u2019Connell JT, Charytan D, Muller GA, Muller CA, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. <i>Nat Med<\/i> 2013; 19: 227\u2013231, doi:10.1038\/nm.2989.","DOI":"10.1038\/nm.2989"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Yamamoto M, Hanatani S, Araki S, Izumiya Y, Yamada T, Nakanishi N, et al. HE4 predicts progressive fibrosis and cardiovascular events in patients with dilated cardiomyopathy. <i>J Am Heart Assoc<\/i> 2021; 10: e021069, doi:10.1161\/JAHA.120.021069.","DOI":"10.1161\/JAHA.120.021069"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ogata F, Hanatani S, Nakashima N, Yamamoto M, Shirahama Y, Ishii M, et al. Human epididymis protein 4 is a useful predictor of post-operative prognosis in patients with severe aortic stenosis. <i>ESC Heart Fail<\/i> 2024; 11: 2924\u20132932, doi:10.1002\/ehf2.14845.","DOI":"10.1002\/ehf2.14845"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. <i>J Am Coll Cardiol<\/i> 2011; 57: 1468\u20131476, doi:10.1016\/j.jacc.2010.11.030.","DOI":"10.1016\/j.jacc.2010.11.030"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Cabac-Pogorevici I, Muk B, Rustamova Y, Kalogeropoulos A, Tzeis S, Vardas P. Ischaemic cardiomyopathy. Pathophysiological insights, diagnostic management and the roles of revascularisation and device treatment. Gaps and dilemmas in the era of advanced technology. <i>Eur J Heart Fail<\/i> 2020; 22: 789\u2013799, doi:10.1002\/ejhf.1747.","DOI":"10.1002\/ejhf.1747"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. <i>Eur Heart J<\/i> 2023; 44: 3503\u20133626, doi:10.1093\/eurheartj\/ehad194.","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. <i>Circulation<\/i> 2006; 113: 1807\u20131816, doi:10.1161\/CIRCULATIONAHA.106.174287.","DOI":"10.1161\/CIRCULATIONAHA.106.174287"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2020; 142: e7\u2013e22, doi:10.1161\/CIR.0000000000000792.","DOI":"10.1161\/CIR.0000000000000792"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, et al. Diagnosis and management of cardiac sarcoidosis: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2024; 149: e1197\u2013e1216, doi:10.1161\/CIR.0000000000001240.","DOI":"10.1161\/CIR.0000000000001240"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease: Executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation<\/i> 2021; 143: e35\u2013e71, doi:10.1161\/CIR.0000000000000932.","DOI":"10.1161\/CIR.0000000000000932"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J<\/i> 2022; 43: 4229\u20134361, doi:10.1093\/eurheartj\/ehac244.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: Recommendations from the American Society of Echocardiography. <i>J Am Soc Echocardiogr<\/i> 2019; 32: 1\u201364, doi:10.1016\/j.echo.2018.06.004.","DOI":"10.1016\/j.echo.2018.06.004"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Hnat T, Veselka J, Honek J. Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. <i>ESC Heart Fail<\/i> 2022; 9: 2070\u20132083, doi:10.1002\/ehf2.13939.","DOI":"10.1002\/ehf2.13939"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Tian M, Zhu X, Ren L, Zhou X, Gu L, Meng K, et al. HE4-based nomogram for predicting overall survival in patients with idiopathic pulmonary fibrosis: Construction and validation. <i>Eur J Med Res<\/i> 2024; 29: 238, doi:10.1186\/s40001-024-01829-0.","DOI":"10.1186\/s40001-024-01829-0"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. de Boer RA, Cao Q, Postmus D, Damman K, Voors AA, Jaarsma T, et al. The WAP four-disulfide core domain protein HE4: A novel biomarker for heart failure. <i>JACC Heart Fail<\/i> 2013; 1: 164\u2013169, doi:10.1016\/j.jchf.2012.11.005.","DOI":"10.1016\/j.jchf.2012.11.005"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Piek A, Meijers WC, Schroten NF, Gansevoort RT, de Boer RA, Sillje HH. HE4 serum levels are associated with heart failure severity in patients with chronic heart failure. <i>J Card Fail<\/i> 2017; 23: 12\u201319, doi:10.1016\/j.cardfail.2016.05.002.","DOI":"10.1016\/j.cardfail.2016.05.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD).  <i>Circ J<\/i> 2009; 73: 1893\u20131900, doi:10.1253\/circj.CJ-09-0254.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction: A report from the CHART-2 Study. <i>Eur J Heart Fail<\/i> 2017; 19: 1258\u20131269, doi:10.1002\/ejhf.807.","DOI":"10.1002\/ejhf.807"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Obokata M, Borlaug BA. The strengths and limitations of E\/e\u2032 in heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2018; 20: 1312\u20131314, doi:10.1002\/ejhf.1250.","DOI":"10.1002\/ejhf.1250"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Park JH, Marwick TH. Use and limitations of E\/e\u2032 to assess left ventricular filling pressure by echocardiography. <i>J Cardiovasc Ultrasound<\/i> 2011; 19: 169\u2013173, doi:10.4250\/jcu.2011.19.4.169.","DOI":"10.4250\/jcu.2011.19.4.169"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Nagueh SF, Sanborn DY, Oh JK, Anderson B, Billick K, Derumeaux G, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography and for heart failure with preserved ejection fraction diagnosis: An update from the American Society of Echocardiography. <i>J Am Soc Echocardiogr<\/i> 2025; 38: 537\u2013569, doi:10.1016\/j.echo.2025.03.011.","DOI":"10.1016\/j.echo.2025.03.011"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Okuno T, Kagami K, Harada T, Hoshiga M, Ishii H, Obokata M. Diagnostic approaches to heart failure with preserved ejection fraction (HFpEF): Identification of unrecognized HFpEF. <i>Circ J<\/i> 2025; 89: 877\u2013884, doi:10.1253\/circj.CJ-25-0214.","DOI":"10.1253\/circj.CJ-25-0214"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Potter E, Marwick TH. Assessment of left ventricular function by echocardiography: The case for routinely adding global longitudinal strain to ejection fraction. <i>JACC Cardiovasc Imaging<\/i> 2018; 11: 260\u2013274, doi:10.1016\/j.jcmg.2017.11.017.","DOI":"10.1016\/j.jcmg.2017.11.017"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2014; 27: 911\u2013939, doi:10.1016\/j.echo.2014.07.012.","DOI":"10.1016\/j.echo.2014.07.012"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Sengelov M, Jorgensen PG, Jensen JS, Bruun NE, Olsen FJ, Fritz-Hansen T, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. <i>JACC Cardiovasc Imaging<\/i> 2015; 8: 1351\u20131359, doi:10.1016\/j.jcmg.2015.07.013.","DOI":"10.1016\/j.jcmg.2015.07.013"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Brann A, Miller J, Eshraghian E, Park JJ, Greenberg B. Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2023; 25: 1755\u20131765, doi:10.1002\/ejhf.2947.","DOI":"10.1002\/ejhf.2947"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Odajima S, Nishimori M, Okamoto H, Hirata KI, Tanaka H. Scoring system for prediction of left ventricular longitudinal myocardial dysfunction in preclinical heart failure patients. <i>Circ J<\/i> 2024; 88: 703\u2013710, doi:10.1253\/circj.CJ-23-0798.","DOI":"10.1253\/circj.CJ-23-0798"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, et al. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV<sub>1<\/sub>) in cystic fibrosis patients receiving ivacaftor treatment. <i>J Cyst Fibros<\/i> 2019; 18: 271\u2013277, doi:10.1016\/j.jcf.2018.08.013.","DOI":"10.1016\/j.jcf.2018.08.013"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Moore RG, Plante B, Hartnett E, Mitchel J, Raker CA, Vitek W, et al. Assessment of serum HE4 levels throughout the normal menstrual cycle. <i>Am J Obstet Gynecol<\/i> 2017; 217: 53.e1\u201353.e9, doi:10.1016\/j.ajog.2017.02.029.","DOI":"10.1016\/j.ajog.2017.02.029"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. <i>JACC Cardiovasc Imaging<\/i> 2018; 11: 48\u201359, doi:10.1016\/j.jcmg.2017.04.006.","DOI":"10.1016\/j.jcmg.2017.04.006"},{"key":"37","doi-asserted-by":"publisher","unstructured":"37. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). <i>J Cardiovasc Magn Reson<\/i> 2017; 19: 75, doi:10.1186\/s12968-017-0389-8.","DOI":"10.1186\/s12968-017-0389-8"},{"key":"38","doi-asserted-by":"publisher","unstructured":"38. Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S. Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: A comprehensive review. <i>J Cardiovasc Magn Reson<\/i> 2016; 18: 89, doi:10.1186\/s12968-016-0308-4.","DOI":"10.1186\/s12968-016-0308-4"},{"key":"39","doi-asserted-by":"publisher","unstructured":"39. Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: Pathophysiology, imaging, and novel therapies. <i>Eur Heart J<\/i> 2022; 43: 2549\u20132561, doi:10.1093\/eurheartj\/ehac223.","DOI":"10.1093\/eurheartj\/ehac223"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40. Linde C, Gold MR, Abraham WT, St John Sutton M, Ghio S, Cerkvenik J, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. <i>Eur Heart J<\/i> 2013; 34: 2592\u20132599, doi:10.1093\/eurheartj\/eht160.","DOI":"10.1093\/eurheartj\/eht160"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, et al. Circulating heart failure biomarkers beyond natriuretic peptides: Review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). <i>Eur J Heart Fail<\/i> 2021; 23: 1610\u20131632, doi:10.1002\/ejhf.2346.","DOI":"10.1002\/ejhf.2346"},{"key":"42","doi-asserted-by":"publisher","unstructured":"42. Nunez J, Bayes-Genis A, Revuelta-Lopez E, Ter Maaten JM, Minana G, Barallat J, et al. Clinical role of CA125 in worsening heart failure: A BIOSTAT-CHF study subanalysis. <i>JACC Heart Fail<\/i> 2020; 8: 386\u2013397, doi:10.1016\/j.jchf.2019.12.005.","DOI":"10.1016\/j.jchf.2019.12.005"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Tang Y, Chen Y, Huang XJ, Hu ZQ, Hu YJ, Peng SL, et al. The level of human epididymis protein 4 is associated with poor prognosis in patients with ejection fraction preserved heart failure. <i>Front Cardiovasc Med<\/i> 2025; 12: 1530271, doi:10.3389\/fcvm.2025.1530271.","DOI":"10.3389\/fcvm.2025.1530271"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/6\/90_CJ-25-0942\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T03:21:17Z","timestamp":1780111277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/6\/90_CJ-25-0942\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-25-0942","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"CJ-25-0942"}}